UNCY
Unicycive Therapeutics IncKey Statistics
About Unicycive Therapeutics Inc
Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to innovating treatments for kidney diseases, with a particular emphasis on addressing hyperphosphatemia. The company is advancing its proprietary therapies aimed at regulating phosphorus levels, which are pivotal in the management of kidney-related disorders. With a robust pipeline supported by a commitment to research and development, along with strategic partnerships to enhance its capabilities, Unicycive is well-positioned to drive significant advancements in nephrology. As its clinical trials progress, Unicycive presents a promising investment opportunity for institutional investors seeking exposure to transformative healthcare solutions.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-29.48M |
| Operating Margin | 0.00% |
| Return on Equity | -141.10% |
| Return on Assets | -45.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.36 |
| Price-to-Book | 6.41 |
| Price-to-Sales (TTM) | 23.75 |
| EV/Revenue | 16.63 |
| EV/EBITDA | -1.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $25.24M |
| Float | $22.82M |
| % Insiders | 2.36% |
| % Institutions | 32.23% |
Historical Volatility
Volatility is currently contracting